{
    "nctId": "NCT00632723",
    "briefTitle": "IRESSA\u2122 (Gefitinib) in Breast Cancer Patients",
    "officialTitle": "A Phase II Trial to Assess the Efficacy of IRESSA\u2122 (Gefitinib) 500 mg/Day in Patients With Breast Cancer Who Have Failed Tamoxifen or Have an Oestrogen Receptor Negative Tumour and Would be Considered for Systemic Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "Objective tumour response (complete + partial response) based on Union International Contre le Cancer (UICC) Criteria",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* histological or cytological confirmation of breast cancer that is either\n\n  * a primary tumour in a patient unfit for or who has declined surgery\n  * advanced (locally or metastatic) disease\n* acquired resistance to tamoxifen or ER negative tumour\n* at least one measurable or assessable lesion\n* WHO performance status 0 - 2\n* life expectancy of 12 weeks or more\n\nExclusion Criteria:\n\n* more than one previous chemotherapy regimens for advanced disease\n* prior anthracycline chemotherapy (\\> 250 mg/m2 adriamycin)\n* radiotherapy completed within 14 days prior to Day 1 of treatment\n* incomplete healing from prior oncologic or other major surgery\n* signs of neurological symptoms consistent with spinal cord compression\n* any evidence of clinically active interstitial lung disease (patients with chronic stable",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}